Vivodyne

Advantages and Impact of FDA’s Plan to Phase Out Animal Testing for mAbs and Other Drugs 🧬🧬 Our CEO & Co-Founder Andrei Georgescu, Ph.D. discusses key advantages of its humanized drug testing platform and the impact of the FDA’s policy shift, with Kristin Brooks, managing editor at Contract Pharma. Read the article: https://lnkd.in/eH4Y9ptC

Andrei Georgescu, Ph.D., the CEO of Vivodyne Inc., told BioWorld that this “is a pivotal moment for biotech. For many decades, drug development has relied on animal models that nearly always fail to accurately predict how therapies will perform in humans. With the FDA now embracing preclinical human data, especially in precision medicines specific to human targets, biotechs have the regulatory tailwind to continue prioritizing their transition to more predictive, translatable preclinical pipelines – like lab-grown tissues that allow testing against real human biology.” Vivodyne uses AI, robotics and human-tissue engineering to generate predictive human data. Its automated platform is used to discover novel targets and develop drugs against them by testing directly in living, functional, lab-grown human tissues, Georgescu said. Read the article: https://lnkd.in/e_8m2tE4

👥 #TechBio startups heading to #AWS Life Sciences Symposium Don’t miss Latent Labs, Manifold Bio, Manifold, QuantHealth, PhaseV, VIDA, Florence Healthcare, Lindus Health, Protai, iktos, Vivodyne, and Rhino Federated Computing, as they join us at the Techbio Lounge on May 6 in NYC as a part of Amazon Web Services (AWS) Life Sciences Symposium, the industry's leading technology event. Be part of the industry's leading event at the intersection of science and technology. 🎟️ Join the waitlist: https://go.aws/43TXnr7 #AWSforLifeSciences #LifeSciences

Thanks FirstWord Pharma and Elizabeth Eaton for featuring Vivodyne in your coverage of the FDA’s major announcement last week. As our COO Julie O'Shaughnessy shared: "The FDA’s decision marks a pivotal moment in drug development — and it reinforces the approach we’ve taken at Vivodyne since day one. Our approach is human from start to finish. By combining lab-grown human tissues, large-scale automation, and multimodal AI, we generate functional, clinically predictive data that increases the success rate of drug discovery and development." 🔗 Read the article here: https://lnkd.in/gJV8F9kB

A balanced take — thanks Ryan Cross & Max Gelman! https://lnkd.in/enNb-tFZ

🐁 FDA just eliminated animal-testing requirements for monoclonal antibodies and other biologics, marking a pivotal shift toward human-driven preclinical pipelines. This directly validates Vivodyne’s core approach: large-scale therapeutic discovery & development powered by whole-tissue functional genomics and drug testing on biopsy-sized, perfusable human tissues. Our platform simultaneously tests on over 10,000 human tissues across 20+ tissue and disease types from diverse donor subpopulations, producing actionable human data before clinical trials. We partner from early discovery to late-stage development to create & optimize biologics and precision modalities (bispecs, cell therapies, advanced targeting, combo tx) that are strongly limited by animal-to-human translation. For BD — our web form is rate-limiting us. Please contact Danielle Scheffey ([email protected]) directly!

🔬 Join Vivodyne – Pioneering the Future of Drug Discovery At Vivodyne, we’re building the next generation of fully human, lab-grown tissues to transform drug discovery—eliminating reliance on animal models and accelerating the path to new treatments. Our interdisciplinary team of scientists, engineers, and AI experts is redefining how medicine is developed. We’re hiring across bioengineering, robotics, hardware design, and AI. If you’re passionate about pushing the boundaries of science and technology to make a real-world impact, we want to hear from you. 🔗 Explore open roles: www.vivodyne.com/careers #Hiring #DrugDiscovery #Bioengineering #AI #Robotics #BiotechCareers

Our CEO & Co-Founder Andrei Georgescu, Ph.D. spoke at the AI Revolutionizing Therapeutic Drug Development panel at #BiotechShowcase #JPM25. Great session moderated by Maria Luisa Pineda, PhD. at Envisagenics and joined by follow panelists Wyatt McDonnell CEO of Infinimmune, Kfir Schreiber CEO, DeepCure, Hannah Wastyk CEO Interface Biosciences and Khai Minh Pham MD, PhD (AI) CEO ThinkingNode Life Science, Inc. Looking forward to sharing more news updates this year! 🧬🧬

Meet with the Vivodyne team at #JPM25! 🧬🧬 Our CEO Andrei Georgescu, Ph.D. and Chief Operating Officer Julie O'Shaughnessy will be on-site Jan 13-15 at the conference. Andrei will also be speaking on the following panel at Biotech Showcase: AI, ML, & LLM: Revolutionizing Therapeutic Development 📍 Biotech Showcase 🌍 San Francisco, CA 📆 January 15, 2025 🕖 14:30 – 15:30 Large language models (LLMs) and artificial intelligence (AI) are transforming the pharmaceutical industry by streamlining processes across the entire drug development lifecycle. These technologies enable researchers to generate hypotheses, extract insights from vast datasets, detect patterns, and simplify literature searches through natural language interactions. Beyond drug discovery, AI has the potential to revolutionize various aspects of therapeutic development, including research, clinical trials, regulatory filings, and manufacturing. Inquiries can be directed to: [email protected]. Looking forward to seeing everyone there!

AI, ML, & LLM: Revolutionizing Therapeutic Development 📍 Biotech Showcase 🌍 San Francisco, CA 📆 January 15, 2025 🕖 14:30 – 15:30 Large language models (LLMs) and artificial intelligence (AI) are transforming the pharmaceutical industry by streamlining processes across the entire drug development lifecycle. These technologies enable researchers to generate hypotheses, extract insights from vast datasets, detect patterns, and simplify literature searches through natural language interactions. Beyond drug discovery, AI has the potential to revolutionize various aspects of therapeutic development, including research, clinical trials, regulatory filings, and manufacturing. This session is open to life science professionals. Take advantage of this opportunity to explore the program and experience what Biotech Showcase has to offer. RSVP is required to reserve your spot! RSVP now >> https://lnkd.in/gHhFJN5S Moderator: Maria Luisa Pineda, PhD.   Panelists: Andrei Georgescu, Ph.D. Wyatt McDonnell Khai Minh Pham MD, PhD (AI) Kfir Schreiber Hannah Wastyk   #BiotechShowcase #SanFrancisco Sara Jane Demy